Three newly synthesized benzamides by the Department of PharmaceuticalChemistry of the Faculty of pharmacy from the University of Medicine and Pharmacy "Carol Davila" Bucharest were tested in order to determine whether these new molecules have similar effects on the central nervous system as those already in therapeutic use belonging to the same chemical group, such as tiapride (neuroleptic) or lidocaine (local anaesthetic).Tests were carried out on NMRI mice which were given new compounds, conventionally named I5C, I14C, and II5C in a dose of 1/20 of the lethal dose 50% (LD50), as previously determined. They received this treatment daily for 21 days.The evasive-investigating capacity of mice was determined using the platform test, and the motor activity using an Activity cage device.The results have shown that compounds I5C and II5C decrease the investigation capacity of the mice; and compound I5C inhibits motor activity, while II5C stimulates it. Thus we concluded that only compounds I5C and II5C have a neuroleptic potential that might be investigated further.Acne conglobata is a rare, severe form of acne vulgaris characterized by the presence of comedones, papules, pustules, nodules and sometimes hematic or meliceric crusts, located on the face, trunk, neck, arms and buttocks.Cornel Chiriță et al.

A series of new compounds with quinazolin-4-one structure, synthesized by the , was studied. Five of them were selected, conventionally named S1, S2, S3, S4, S5, and investigated in terms of their potential influence on the central nervous system (CNS). For this purpose, the antidepressant effect was determined using the forced swimming test; the anxiolytic/ anxiogenic effect was determined using the suspended plus-shaped maze (Ugo Basile); the effect on the motor activity was determined using the Ugo Basile activity cage; and the potential analgesic effect was investigated using the hot plate test (Ugo Basile). Compounds S3 and S5 lowered the motor activity and showed an anxiolytic effect, while S1 and S2 proved to have antidepressant and analgesic effects.A good correlation between antidepressant and analgesic effects was observed, consistent with the fact that analgesic drugs, by increasing norepinephrine and serotonin levels in the pain inhibiting descendent pathways, can be used as co-analgesics in therapy.  quinazolin-4-one derivatives, antidepressant, anxiolytic, analgesic, pharmacological research Highlights  S1 and S2 reduced the immobilization time in the forced swimming test by 25.98%, respectively 28.45%  S3 and S5 have been shown to have relatively similar pharmacological profiles with respect to influence on HMA and VMA Keywords

The severity and complexity of depression can vary widely among individuals, thus making single drug therapy ineffective in some cases. Taking this fact into account and using a mouse model, we set on investigating the possibility of obtaining a synergism of action between a classical tricyclic antidepressant that inhibits noradrenalin and serotonin reuptake (doxepin), and a modern antidepressant that inhibits type-B monoamine oxidase (selegiline). We measured the antidepressant effect using the forced swimming test and the tail suspension test. We determined motor activity using the Activity Cage test. Our results have shown that the antidepressant effect intensifies significantly in the animals treated with both antidepressants simultaneously compared to those treated only with doxepin. Furthermore, we observed that selegiline decreases the sedative effect of doxepin in the Activity Cage test.

Non-adherence to antihypertensive medication is commonly associated with suboptimal clinic outcomes but is nonetheless a common behaviour. This observational study investigated medication adherence of hypertensive Romanian patients using the Morisky-Green-Levine questionnaire. 22.2% of patients had low adherence, 51.3% of patients had moderate adherence and 26.5% had high adherence. Investigating the influence of age, sex, education, medication regimen complexity, comorbidities and information about medicines offered by the pharmacist to the patient on adherence levels, the most important positive predictor of adherence was the educational level. For patients having finished secondary school and patients with primary school, odd ratios to be in a higher category of adherence, compared to university graduates, were 0.62 and 0.53 respectively. Another significant predictor of adherence was the drug regimen, the increasing number of daily medicines and nutritive supplements reducing adherence. Rezumat Non-aderența la medicația antihipertensivă este frecvent asociată cu rezultate clinice suboptimale, și totuși este un comportament des întâlnit. Prezentul studiu observațional a determinat gradul de aderență la medicație al pacienților hipertensivi români, evaluat cu ajutorul chestionarului Morisky-Green-Levine. 22,2% dintre pacienți au avut o aderență scăzută, 51,3% dintre pacienți au avut o aderență moderată și 26,5% au avut o aderență ridicată. Studiul a investigat influența vârstei, sexului, nivelului de educație, regimului medicamentos, comorbidităților și tipului de informații despre medicament furnizate de farmacist asupra aderenței. Cel mai important predictor al aderenței înalte a fost nivelul de școlarizare. Șansele ca pacienții absolvenți de liceu să fie într-o categorie superioară de aderență, comparativ cu un absolvent de facultate sunt 0,62, iar cele ale pacienților care au terminat doar gimnaziul sunt 0,53. Alt predictor semnificativ al aderenței a fost regimul medicamentos, aderența scăzând cu creșterea numărului de pastile administrate zilnic.

only few applications are currently dealing with personalized adverse drug reactions (ADRs) prediction in case of polypharmacy. the study aimed to develop a patient-tailored ADR web application, considering characteristics from 734 drugs and relevant patient related factors. The application was designed in python using a scoring and ranking system based on frequency and severity, computed for each ADR and expressed through an online platform. A neural networks algorithm was used for predicting the severity of ADRs. the application inputs are: age, gender, drugs, relevant pathologies. The outputs are: an overall severity profile (hospitalization and mortality risk), a stratified risk on specific ADR groups and a sorted list of the most important ADRs depending on frequency and severity. The Severity prediction model validation resulted in 79.7-85.1% Area Under the Receiver Operating Characteristic Curve Score, which lies in the good cutoff of 75-90%. The program offers a complex view regarding the ADR profile of a given patient and could be used by the physician and clinical pharmacist during patient safety monitoring, for a coherent therapy choice or medication adjustment, due to the good therapy coverage and the inclusion of relevant patient comorbidities. Currently, adverse drug reactions (ADRs) represent major worldwide health issues, due to their negative impact on the quality of life and outcome of patients receiving multiple drug therapy. It is believed that almost 10% of the in-patients usually develop at least one ADR during hospitalization, while almost 50% of all ADRs appear prior to the admission 1-5. The major risk factors which specifically influence the development of ADRs are age, gender, ethnicity, pregnancy, multiple pathology, polypharmacy, drug dosage and frequency of administration, genetic polymorphism or special conditions (renal impairment, hepatic impairment) 6-9. The complex combination of these factors leads to the need of implementing precision medicine in case of a drug therapy for a certain patient 10. Therefore, the consideration of a patient-tailored ADR profile becomes of an utmost importance when choosing the best drug combination and during the patient safety monitoring. Several standardized databases containing valuable information regarding ADRs can be found, which could aid in extracting the information for such purposes. Among them, PROTECT ADR database lists all the ADRs and additional information derived from the Summaries of Product Characteristics of a high number of centrally authorized products by the European Medicines Agency 11. A prediction of the ADRs which are likely to appear for a certain patient considered pre-clinical data and spontaneous reports and was described by Ngufor and Wojtusiak 12 , which took into account the specific drug information and known ADRs from DrugBank and Side Effect Resource Database (SIDER), as well as drug-event signals and demographics from Food and Drug Administration Adverse Event Reporting System (FAERS) and MedEffect. In terms of ...